Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study aims to analyze the efficacy and safety of passive immunotherapy by administering an equine hyperimmune serum (INM005) against the SARS-CoV2 RBD to Covid19 patients. Improvement of the clinical course 28 days after the start of treatment will be evaluated.
Description: The primary endpoint will be the proportion of patients who show a change in symptoms 28 days after the administration of the first dose. A responding subject is defined as a subject with improvement in at least 2 categories on the 8-point World Health Organization (WHO) ordinal scale of clinical status or a subject who is discharged.
Measure: Clinical changes in COVID-19 symptoms Time: 4 weeksDescription: INM005 product concentration in serum at different time points after dosing
Measure: Pharmacokinetics evaluation of INM005 Time: 1 weekDescription: Time to achieve a change in at least 2 categories on the 8-point WHO ordinal scale of clinical status. Time to discharge (days). Time to intensive care unit (ICU) discharge (days).
Measure: Time to progression of disease Time: 4 weeksDescription: Proportion of patients who present change in at least 2 categories on the 8-point WHO ordinal scale of clinical status at 7 and 14 days after the start of the treatment.
Measure: Disease progression Time: up to 2 weeksDescription: Proportion of patients discharged at 28 days
Measure: Discharge Time: up to 4 weeksDescription: Proportion of patients who require ICU hospitalization
Measure: Intensive care unit (ICU) hospitalization Time: up to 4 weeksDescription: Proportion of patients who require MVA
Measure: Mechanical ventilation assistance (MVA) Time: up to 4 weeksDescription: Proportion of patients who die due to complications from COVID19
Measure: Mortality Time: up to 4 weeksDescription: Change in viral load from baseline to 7 and 21 days after the start of the treatment.
Measure: Changes in viral load Time: up to 3 weeksDescription: Measurement of anti SARS-CoV2 antibodies titer levels. IgG (0, 21 days)
Measure: Anti SARS-CoV2 antibodies levels Time: 3 weeksDescription: Changes in Troponin T levels will be evaluated at 7 and 21 days as a measurement of disease progression
Measure: Changes in Troponin T levels Time: 3 weeksDescription: Changes in D-dimer levels will be evaluated at 7 and 21 days as a measurement of disease progression
Measure: Changes in D-dimer levels Time: 3 weeksDescription: Changes in Ferritin levels will be evaluated at 7 and 21 days as a measurement of disease progression
Measure: Changes in Ferritin levels Time: 3 weeksDescription: Changes in LDH levels will be evaluated at 7 and 21 days as a measurement of disease progression
Measure: Changes in LDH levels Time: 3 weeksDescription: Changes in C-reactive protein levels will be evaluated at 7 and 21 days as a measurement of disease progression
Measure: Changes in C-reactive protein levels Time: 3 weeksDescription: Measurement of anti-INM005 antibodies: baseline and 21 days
Measure: Immunogenicity Time: 3 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports